OncoMatch/Clinical Trials/NCT04778956
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Is NCT04778956 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Toripalimab for nasopharyngeal carcinoma.
Treatment: Toripalimab — Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of patients with resectable locally recurrent nasopharyngeal carcinoma compared with those treated with salvage surgery alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RECURRENT T1, RECURRENT T2, RECURRENT T3, RECURRENT N1, RECURRENT N2, RECURRENT N3 (8th edition of American Joint Committee on Cancer (AJCC) staging system for nasopharyngeal carcinoma)
Resectable nasopharyngeal diseases: recurrent T1...T2...T3...Resectable recurrent regional lymph node diseases (recurrent N1-3)...(according to the 8th edition of American Joint Committee on Cancer (AJCC) staging system for nasopharyngeal carcinoma)
Performance status
KARNOFSKY 71–100
Karnofsky Performance Status (KPS) ≤70 [excluded]
Prior therapy
Must have received: radiotherapy
The recurrence time is more than 6 months from the end of radiotherapy.
Cannot have received: PD-1/PD-L1/CTLA-4 inhibitor
Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) agent.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify